We are live on
!
Find out more
GCM
Gladius Capital Management Portfolio holdings
AUM
$1.65B
1-Year Est. Return
25.75%
This Fund
S&P 500
This Quarter
Est. Return
+6.29%
1 Year Est. Return
+25.75%
3 Year Est. Return
+78.03%
5 Year Est. Return
+67.88%
10 Year Est. Return
+218.88%
AUM
$1.72B
AUM Growth
+$325M
(+23%)
Cap. Flow
+$219M
Cap. Flow
% of AUM
12.75%
Top 10 Holdings %
Top 10 Hldgs %
55.41%
Holding
448
New
102
Increased
117
Reduced
145
Closed
81
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$89.1M |
| 2 |
Invesco QQQ Trust
QQQ
|
+$15.7M |
| 3 |
JPMorgan Chase
JPM
|
+$6.39M |
| 4 |
Bank of America
BAC
|
+$4.74M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$3.72M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$34.1M |
| 2 |
iShares MSCI Emerging Markets ETF
EEM
|
+$28.3M |
| 3 |
UnitedHealth
UNH
|
+$20.4M |
| 4 |
NVIDIA
NVDA
|
+$20.2M |
| 5 |
Walmart Inc
WMT
|
+$10.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 1.29% |
| 2 | Healthcare | 1.06% |
| 3 | Consumer Staples | 0.73% |
| 4 | Technology | 0.61% |
| 5 | Consumer Discretionary | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Ironwood Pharmaceuticals
IRWD
$701M
| $32.3K | ﹤0.01% |
3,072
-104
| -3% | -$1.17K |
|
|
NWLI
277
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $32.3K | ﹤0.01% |
133
-47
| -26% | -$12.2K |
|
278
F&G Annuities & Life
FG
$3.87B
| $32.1K | ﹤0.01% |
+1,769
| New | +$35.4K |
|
279
Innoviva
INVA
$1.53B
| $32K | ﹤0.01% |
2,846
-65
| -2% | -$789 |
|
280
Vanda Pharmaceuticals
VNDA
$309M
| $32K | ﹤0.01% |
4,707
+1,229
| +35% | +$8.64K |
|
281
HF Sinclair
DINO
$14.7B
| $31.8K | ﹤0.01% |
657
+40
| +6% | +$2.08K |
|
|
HDSN
282
Hudson Technologies
HDSN
$238M
| $31.4K | ﹤0.01% |
+3,597
| New | +$34.8K |
|
|
ZYXI
283
DELISTED
Zynex
ZYXI
| $30.9K | ﹤0.01% |
2,577
-206
| -7% | -$2.69K |
|
284
Cullinan Oncology
CGEM
$1.16B
| $30.5K | ﹤0.01% |
2,978
-16
| -0.5% | -$176 |
|
|
EGRX
285
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $29.8K | ﹤0.01% |
1,052
-2
| -0.2% | -$59 |
|
|
CCRN
286
DELISTED
Cross Country Healthcare
CCRN
| $29.7K | ﹤0.01% |
1,331
+260
| +24% | +$6.81K |
|
287
Collegium Pharmaceutical
COLL
$944M
| $29.6K | ﹤0.01% |
1,235
-478
| -28% | -$12.7K |
|
288
Organogenesis Holdings
ORGO
$310M
| $29.5K | ﹤0.01% |
13,833
+120
| +0.9% | +$296 |
|
|
SPTN
289
DELISTED
SpartanNash
SPTN
| $29.4K | ﹤0.01% |
+1,184
| New | +$34.1K |
|
290
Orthofix Medical
OFIX
$432M
| $29K | ﹤0.01% |
1,733
-285
| -14% | -$5.58K |
|
|
AEL
291
DELISTED
American Equity Investment Life Holding Company
AEL
| $28.7K | ﹤0.01% |
786
-152
| -16% | -$6.46K |
|
292
Viatris
VTRS
$19B
| $28.5K | ﹤0.01% |
2,960
-458
| -13% | -$5.08K |
|
293
SIGA Technologies
SIGA
$224M
| $28.3K | ﹤0.01% |
4,930
+690
| +16% | +$4.61K |
|
294
Vir Biotechnology
VIR
$1.48B
| $28.3K | ﹤0.01% |
1,216
-148
| -11% | -$3.79K |
|
|
AAN
295
DELISTED
The Aaron's Company Inc
AAN
| $28.3K | ﹤0.01% |
2,928
-3,226
| -52% | -$41.4K |
|
296
Organon & Co
OGN
$3.56B
| $28.1K | ﹤0.01% |
1,195
-229
| -16% | -$6.15K |
|
|
EQRX
297
DELISTED
EQRx, Inc. Common Stock
EQRX
| $28.1K | ﹤0.01% |
+14,473
| New | +$33K |
|
298
Emergent Biosolutions
EBS
$272M
| $28.1K | ﹤0.01% |
2,709
-404
| -13% | -$4.88K |
|
|
MDRX
299
DELISTED
Veradigm Inc. Common Stock
MDRX
| $27.7K | ﹤0.01% |
+2,126
| New | +$34.4K |
|
|
TRUE
300
DELISTED
TrueCar
TRUE
| $27.6K | ﹤0.01% |
12,021
-2,367
| -16% | -$6.31K |
|
Similar funds
ACM
BFPW
RIA
GACM
GA
LIA
GWM
Gladius Capital Management's Q1 2023 Portfolio in Review
As of Q1 2023, Gladius Capital Management held 448 positions worth $1.72B, up 23% from $1.39B the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Gladius Capital Management deployed $219M of net new capital in Q1 2023, opening 102 new positions and adding to 117 existing holdings. Its largest new stake was Invesco QQQ Trust: 53,172 shares worth $17.1M.
By sector, the portfolio is most concentrated in Financials at 1.3% of assets, up from 0.78% a quarter earlier, followed by Healthcare and Consumer Staples.
On the sell side, the largest reduction was iShares MSCI Emerging Markets ETF, an estimated $28.3M trimmed.
- Gladius Capital Management's largest Q1 2023 buy was Invesco QQQ Trust: 53,172 shares worth $17.1M.
- Gladius Capital Management added most to State Street SPDR S&P 500 ETF Trust in Q1 2023, an estimated $89.1M increase.
- Gladius Capital Management's biggest Q1 2023 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $28.3M.
- Gladius Capital Management fully exited Apple in Q1 2023, selling an estimated $34.1M.
- Gladius Capital Management's ten largest holdings make up 55% of its $1.72B portfolio in Q1 2023.
- Gladius Capital Management opened 102 new positions and closed 81 in Q1 2023.
- Gladius Capital Management's portfolio value rose 23% quarter-over-quarter to $1.72B.
Based on Gladius Capital Management's 13F filing for Q1 2023, filed 9 May 2023.